
Supplement Novilora Launches in US for CIPN Support
The supplement, sold in Europe as OnLife, was evaluated in the single-arm STEFANO study of 146 patients with paclitaxel- or oxaliplatin-induced CIPN.
Novilora, a dietary supplement that combines palmitoylethanolamide (PEA) with a defined profile of fatty acids, launched for presale in the United States on November 17, 2026, as a nerve health product for people with chemotherapy-induced peripheral neuropathy (CIPN), according to a news release from the company.1 The formulation, sold in Europe as OnLife, is not an FDA-approved drug, and its supporting data come from an observational study without a control group.1,2
The product was formulated by Raffaele Migliaccio, an Italian internist and oncologist. Per the release, Novilora "is not intended to diagnose, treat, cure or prevent any disease."1
Why does CIPN matter during and after cancer treatment?
CIPN can cause numbness, tingling, burning, weakness, and balance problems, most often in the hands and feet, and can also affect autonomic function, including heart rate, gastrointestinal function, and sleep-wake cycles.1 An estimated 9.8 million people worldwide needed first-course chemotherapy in 2018, a figure projected to reach 15 million annually by 2040.3 A meta-analysis reported CIPN prevalence of approximately 68% within the first month after chemotherapy and 30% at 6 months or later.4
"Chemotherapy can save and extend lives, but for many patients, its effects do not simply disappear when treatment ends," Migliaccio said in the release. "Peripheral neuropathy can affect something as basic as walking comfortably, maintaining balance, buttoning a shirt or sleeping through the night."1
What did the STEFANO study evaluate?
STEFANO (NCT03065478) was a prospective, single-arm observational study conducted at 21 office-based oncology practices in Germany.2 It included adults with established CIPN after (neo)adjuvant paclitaxel for breast cancer or oxaliplatin-based therapy for colon cancer. Patients took OnLife as 2 tablets daily for 3 months, starting after chemotherapy ended.
Of 146 patients analyzed, 75 had breast cancer and 71 had colon cancer; 83.6% completed the 3-month course. The primary end point was the change in physician-graded peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) from baseline to the end of supplementation.2
What results did STEFANO report?
Improvement was defined as a reduction of at least 1 grade.2
- Breast cancer cohort: PSN improved in 31.1% and stabilized in 54.1%; PMN improved in 37.5% and stabilized in 50.0%.
- Colon cancer cohort: PSN improved in 16.9% and stabilized in 56.3%; PMN improved in 20.0% and stabilized in 50.0%.
- Patient-reported outcomes (EORTC QLQ-CIPN20): 45.9% and 37.5% of patients with paclitaxel-induced sensory and motor neuropathy, respectively, reported fewer symptoms, as did 23.9% and 22.0% of those with oxaliplatin-induced neuropathy.
- Quality of life (EORTC QLQ-C30): mean global health status scores rose by 13.1 points in the breast cohort and 11.5 points in the colon cohort.
Twenty-four patients stopped early, 9 of them because of intolerance, including gastrointestinal intolerance, hypersensitivity, and smell or taste intolerance. The publication did not include a full adverse event table.2
What are the limitations of the evidence?
The investigators noted that the single-arm design may hamper interpretation; without a control group, any effect of the supplement cannot be separated from recovery that occurs after chemotherapy stops. The analysis was exploratory, with no hypothesis testing, and a large share of patient-reported data were not evaluable, reaching 43.7% to 48.0% in the colon cohort. The study was funded by Swiss Medical Food AG, and the authors recommended a randomized multicenter trial.2
For context, the 2020 ASCO guideline update recommends no agents for CIPN prevention and identifies duloxetine as the only agent with appropriate evidence for established painful CIPN, while noting its benefit is limited.6
What are the key takeaways for oncology nurses?
- Ask about supplements at every visit. Patients may encounter Novilora marketing; include it in medication reconciliation and review it with the oncology team and pharmacist.
- Set expectations. The product is marketed as a supplement, not an FDA-approved treatment, and its data come from a single-arm study.
- Use patient-reported measures. Clinician grading may underestimate CIPN severity.5
- Monitor function. Ask about balance, falls, fine motor tasks, and sleep.
- Escalate intolerable symptoms during treatment so dose delays, reductions, or substitutions can be considered.6
References
- Novilora launches in the U.S. to support nerve health for people impacted by chemotherapy-induced peripheral neuropathy. News release. Novilora. November 17, 2026. Accessed November 17, 2026.
https://novilora.com/ - Zaiss M, Uhlig J, Zahn MO, et al. Improving chemotherapy-induced peripheral neuropathy in patients with breast or colon cancer after end of (neo)adjuvant therapy: results from the observational study STEFANO. Oncol Res Treat. 2021;44(11):613-621. doi:10.1159/000519000
- Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
- Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461-2470. doi:10.1016/j.pain.2014.09.020
- Conroy R. CIPN persists years after frontline lymphoma therapy, study findings show. Oncology Nursing News. May 15, 2026. Accessed November 17, 2026.
https://www.oncnursingnews.com/view/cipn-persists-years-after-frontline-lymphoma-therapy-study-findings-show - Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
Related to this article








